ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting po
September 14, 2017Meanwhile, after unveiling its own cardiovascular outcomes data at ADA, rival Johnson & Johnson will have subanalyses of its own to present later in the week. -
Extended use of AZ’ Brilinta cuts CV death risk 29%
August 25, 2017Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Pharma Sources Insight January 2025
